PARP1 and triple-negative breast carcinoma: While there are no reported applications of CRISPR/Cas9 for triple negative breast cancer (TNBC) thus far, it is established that 80% of BRCA1 mutations lead to the development of TNBC, and CRISPR/Cas applications can potentially target the poly (ADP-ribose) polymerase 1 (PARP1) gene, which is responsible for synthetic lethality in BRCA1 deficient cells [37].